In a phase I/Ib study reported last year, personalized neoantigen vaccination in glioblastoma patients increased tumor infiltrating cells, accompanied by a circulating polyfunctional neoantigen-specific CD4+ and CD8+ T cell responses enriched in memory phenotype, in patients who did not received dexamethasone (183). This evidence concerns the gene CD4 and neoplasm.